112 related articles for article (PubMed ID: 23278152)
1. Who will have the best response to entecavir?
Wong GL
J Gastroenterol Hepatol; 2013 Jan; 28(1):5-7. PubMed ID: 23278152
[No Abstract] [Full Text] [Related]
2. [Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B patients].
Yao GB; Ren H; Xu DZ; Zhou XQ; Jia JD; Wang YM; Chen CW
Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):881-6. PubMed ID: 20038326
[TBL] [Abstract][Full Text] [Related]
3. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
[TBL] [Abstract][Full Text] [Related]
4. Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir.
Wang CC; Tseng KC; Peng CY; Hsieh TY; Lin CL; Su TH; Tseng TC; Hsu CS; Lin HH; Kao JH
J Gastroenterol Hepatol; 2013 Jan; 28(1):46-50. PubMed ID: 22989322
[TBL] [Abstract][Full Text] [Related]
5. [Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis].
Xu Y; Wang JB; Xu J; Jiao J; Zhang YG; Ji SW; Zhao P; Guo HH; Li Y; Zhou CY
Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):109-12. PubMed ID: 20196949
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of the therapeutical effects of entecavir and lamvudine in treatment of HBeAg-positive chronic hepatitis B].
Hou HB; Deng LN; Li CP; Liu XR; Liu FQ
Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):873-4. PubMed ID: 19958652
[No Abstract] [Full Text] [Related]
7. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
Sherman M; Yurdaydin C; Simsek H; Silva M; Liaw YF; Rustgi VK; Sette H; Tsai N; Tenney DJ; Vaughan J; Kreter B; Hindes R;
Hepatology; 2008 Jul; 48(1):99-108. PubMed ID: 18537189
[TBL] [Abstract][Full Text] [Related]
8. Changing landscape of antiviral resistance management in chronic hepatitis B.
Nguyen T; Locarnini S; Desmond P
J Gastroenterol Hepatol; 2008 Sep; 23(9):1314-7. PubMed ID: 18853991
[No Abstract] [Full Text] [Related]
9. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.
Shouval D; Lai CL; Chang TT; Cheinquer H; Martin P; Carosi G; Han S; Kaymakoglu S; Tamez R; Yang J; Tenney D; Brett-Smith H
J Hepatol; 2009 Feb; 50(2):289-95. PubMed ID: 19070393
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of efficacy between adefovir dipivoxil and entecavir in patients with chronic hepatitis B].
Yang F; Wu XF; Wei N
Zhonghua Gan Zang Bing Za Zhi; 2010 Jan; 18(1):65-6. PubMed ID: 20128975
[No Abstract] [Full Text] [Related]
11. [Predictors for virologic response in management of chronic hepatitis B].
Lee JM; Ahn SH
Korean J Hepatol; 2010 Mar; 16(1):1-4. PubMed ID: 20375637
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of entecavir in chronic hepatitis B patients with persistently normal alanine aminotransferase: randomized, double-blind, placebo-controlled study.
Tseng KC; Chen CY; Tsai HW; Chang TT; Chuang WL; Hsu PI; Liu WC; Cheng PN
Antivir Ther; 2014; 19(8):755-64. PubMed ID: 24583931
[TBL] [Abstract][Full Text] [Related]
14. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B.
Güzelbulut F; Ovünç AO; Oetinkaya ZA; Senates E; Gökden Y; Saltürk AG; Sezikli M; Ozkara S; Cetinkaya F
Hepatogastroenterology; 2012; 59(114):477-80. PubMed ID: 21940383
[TBL] [Abstract][Full Text] [Related]
16. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
[TBL] [Abstract][Full Text] [Related]
17. Head-To-Head Comparison of Two Years Efficacy of Entecavir and Tenofovir in Patients with Treatment-Naïve Chronic Hepatitis B--The Real Life Data.
Hepatogastroenterology; 2015 Jun; 62(140):982-6. PubMed ID: 26902041
[TBL] [Abstract][Full Text] [Related]
18. Changes in liver stiffness measurement during antiviral therapy in patients with chronic hepatitis B.
Lim SG; Cho SW; Lee YC; Jeon SJ; Lee MH; Cho YJ; Kim SS; Kim YB; Seok JY; Cheong JY; Kim JH
Hepatogastroenterology; 2011; 58(106):539-45. PubMed ID: 21661428
[TBL] [Abstract][Full Text] [Related]
19. Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA.
Kim DH; Choi JW; Seo JH; Cho YS; Won SY; Park BK; Jeon HH; Shin SY; Lee CK
Yonsei Med J; 2017 May; 58(3):552-556. PubMed ID: 28332360
[TBL] [Abstract][Full Text] [Related]
20. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]